Activating FLT3 mutations in CD117/KIT+ T-cell acute lymphoblastic leukemias
E Paietta, AA Ferrando, D Neuberg, JM Bennett… - Blood, 2004 - ashpublications.org
E Paietta, AA Ferrando, D Neuberg, JM Bennett, J Racevskis, H Lazarus, G Dewald…
Blood, 2004•ashpublications.orgActivating FLT3 mutations are the most common genetic aberrations in acute myeloid
leukemia (AML), resulting in the constitutive activation of this receptor tyrosine kinase (RTK),
but such mutations are rarely found in acute lymphoblastic leukemia (ALL). Here we
describe a unique subset of de novo adult T-cell ALL (T-ALL) cases that coexpress
CD117/KIT and cytoplasmic CD3 (CD117/KIT+ ALL). Activating mutations in the FLT3 RTK
gene were found in each of 3 CD117/KIT+ cases that were analyzed, but not in 52 other …
leukemia (AML), resulting in the constitutive activation of this receptor tyrosine kinase (RTK),
but such mutations are rarely found in acute lymphoblastic leukemia (ALL). Here we
describe a unique subset of de novo adult T-cell ALL (T-ALL) cases that coexpress
CD117/KIT and cytoplasmic CD3 (CD117/KIT+ ALL). Activating mutations in the FLT3 RTK
gene were found in each of 3 CD117/KIT+ cases that were analyzed, but not in 52 other …
Abstract
Activating FLT3 mutations are the most common genetic aberrations in acute myeloid leukemia (AML), resulting in the constitutive activation of this receptor tyrosine kinase (RTK), but such mutations are rarely found in acute lymphoblastic leukemia (ALL). Here we describe a unique subset of de novo adult T-cell ALL (T-ALL) cases that coexpress CD117/KIT and cytoplasmic CD3 (CD117/KIT+ ALL). Activating mutations in the FLT3 RTK gene were found in each of 3 CD117/KIT+ cases that were analyzed, but not in 52 other adult T-ALL samples from the same series that lacked CD117/KIT expression. Our results indicate the need for clinical trials to test the efficacy of drugs that inhibit the FLT3 RTK in this subset of patients with T-ALL. (Blood. 2004;104:558-560)
ashpublications.org
